In all, 460 patients with KRAS wild-type tumours who had not previously received EGFR therapy were randomly allocated to irinotecan (230 patients) or IrPan (230 patients), and these form our primary population for this report (Figure 1, Figure 2; appendix). Here, EGFR is linked to neoplasm.